Eli Lilly and Company ($LLY) Stock Forecast: Up 3.1% Today

What is Eli Lilly and Company?

Eli Lilly (LLY) is a pharmaceutical company known for its innovative medicines and strong market presence. Today, the stock experienced a significant bullish movement in the market.

Why is Eli Lilly and Company going up?

LLY stock is up 3.1% on Feb 6, 2025 15:28

• Q4 earnings report for Eli Lilly exceeded expectations, showing a 45% YoY revenue increase driven by strong demand for Mounjaro and Zepbound.
• The company's 2025 sales forecast of $58B-$61B, with a 32% growth midpoint, fueled investor optimism and contributed to the bullish momentum in the stock.
• Analysts are bullish on LLY, with price targets averaging $1066, indicating a 27% upside potential, supported by the anticipated success of new medicines and expanded market launches.
• The positive sentiment surrounding Eli Lilly's earnings and future prospects likely led to the strong bullish movement in the stock today.

LLY Price Chart

LLY Technical Analysis

LLY News

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines - Eli Lilly ( NYSE:LLY )

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth midpoint, led by new medicines and expanded market launches.

https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sa

Eli Lilly ( LLY ) Q4 Earnings and Revenues Top Estimates

Lilly (LLY) delivered earnings and revenue surprises of 5.77% and 0.44%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2410795/eli-lilly-lly-q4-earnings-and-revenues-top-estimates

Eli Lilly Bulls Take Charge Ahead Of Q4 - Can It Reach $1000? - Eli Lilly ( NYSE:LLY )

LLY stock is trading above key moving averages, signaling strong bullish momentum ahead of Q4 earnings. Analysts see a 27% upside, with price targets averaging $1066-will earnings justify the optimism? NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts

https://www.benzinga.com/general/health-care/25/02/43507636/eli-lilly-bulls-charge-q4-earnings-1000-price-sight

What To Expect When Eli Lilly Reports Q4 Earnings On Thursday? - Eli Lilly ( NYSE:LLY )

Eli Lilly expects 2024 revenue to be $45 billion, with Mounjaro and Zepbound sales contributing significantly. The company aims to increase Zepbound's market share, competing with Novo Nordisk's Wegovy. Eli Lilly And Co LLY will announce its fourth-quarter 2024 financial results and 2025 ...

https://www.benzinga.com/25/02/43505148/what-to-expect-when-eli-lilly-reports-q4-earnings-on-thursday

What Thursday's Earnings Mean for This Pharma Giant

LLY is reporting earnings tomorrow and the options market predicts major moves. Tomorrow, Eli Lilly ( LLY ) , the world's largest drug company, reports earnings before the market opens. The options market is already predicting some major moves.

https://www.benzinga.com/trading-ideas/25/02/43482721/what-thursdays-earnings-mean-for-this-pharma-giant

Trending Today

Pyth Network ($PYTH) Crypto Forecast: Down 5.1% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 6.2% Today

Cardano ($ADA) Crypto Forecast: Down 5.3% Today

Litecoin ($LTC) Crypto Forecast: Down 5.2% Today

Pepe ($PEPE) Crypto Forecast: Down 5.0% Today

TRON ($TRX) Crypto Forecast: Down 5.0% Today

Movement ($MOVE) Crypto Forecast: Down 7.6% Today

Ondo ($ONDO) Crypto Forecast: Down 7.9% Today

Dogecoin ($DOGE) Crypto Forecast: Down 6.3% Today

Bittensor ($TAO) Crypto Forecast: Down 5.5% Today

Eli Lilly and Company Price History

30.09.2024 - LLY Stock was down 8.2%

• Disappointing third-quarter earnings and sales were reported by Eli Lilly, missing estimates for both metrics.
• Sales of key products such as Mounjaro and Zepbound also fell below expectations, contributing to the stock's decline.
• The company's lowered 2024 guidance and the significant hit to profit further fueled negative sentiment among investors, leading to an 11% decline in the stock.
• The market reaction indicates that investors were not pleased with the company's performance and outlook, causing a sharp decline in the stock price.

30.09.2024 - LLY Stock was down 13.6%

• Eli Lilly (LLY) reported Q3 earnings and revenue below estimates, leading to a -22.37% surprise in earnings and a 4.92% miss in revenue.
• The company's third-quarter earnings were impacted by a more than double increase in Mounjaro sales but took a $2.98 billion hit to profit, causing the stock to plummet.
• Despite an impressive 51% year-to-date gain, speculation around a stock split, and focus on tirzepatide medicines like Mounjaro and Zepbound, the missed revenue consensus and lowered annual outlook contributed to the bearish movement.
• Additionally, the release of new data on donanemab potentially providing a path to improved profiles might not have been enough to offset the negative impact of the earnings miss and lowered guidance.

15.10.2024 - LLY Stock was down 5.7%

• Detailed results from the Phase 3 SURMOUNT-1 three-year study for tirzepatide led to investor disappointment, influencing the bearish sentiment towards Eli Lilly.
• Unusual options activity from substantial investors indicated a bearish stance, potentially contributing to the stock's decline.
• Criticism from a humanitarian organization about high insulin prices by insulin manufacturers, including Eli Lilly, raised concerns about regulatory challenges or public backlash.
• Despite weaker sales of Mounjaro and Zepbound in the third quarter, growth opportunities for Eli Lilly suggest that the current bearish movement may be a temporary market reaction rather than a long-term trend.

08.10.2024 - LLY Stock was up 5.1%

• Market whales making bullish bets on LLY options indicate confidence in the company's future prospects.
• The positive sentiment towards high-growth stocks may have spilled over to Eli Lilly, contributing to its bullish movement.
• Analysts assessing Eli Lilly's performance against competitors in the pharmaceutical industry might have highlighted its strengths, boosting investor confidence.
• Overall, the combination of bullish options activity, positive market sentiment, and favorable industry comparisons likely propelled Eli Lilly's stock to a strong bullish movement today.

20.11.2024 - LLY Stock was up 5.2%

• Eli Lilly's stock rose notably following the endorsement from the European Medicines Agency (EMA) panel for expanded use of Omvoh in treating Crohn's Disease, underscoring the company's dedication to developing effective treatments.
• Despite another company's weight loss drug not meeting expectations, Eli Lilly's positive updates overshadowed any potential negativity in the pharmaceutical sector.
• The bearish options trends in Eli Lilly's stock may have been counterbalanced by the favorable endorsement from the CHMP, boosting investor confidence and fueling the upward trend.
• With speculation around the next trillion-dollar company, Eli Lilly's progress in healthcare solutions positions it well for potential future growth and market valuation.

26.10.2024 - LLY Stock was up 5.4%

• The bullish movement in Eli Lilly's stock may be linked to the Biden-Harris Administration's proposed rule to expand coverage of anti-obesity medications for Americans with Medicare and Medicaid, potentially boosting investor confidence in the company's sales and revenue prospects.
• Insider purchases by figures like Ralph Alvarez and J. Erik Fyrwald could have also positively influenced market sentiments around Eli Lilly, with insider buying typically regarded as a signal of confidence in the company's future.
• Despite recent challenges and a decline in stock price over the past month, these insider purchases and favorable regulatory updates appear to have eclipsed previous concerns, resulting in the significant bullish movement in Eli Lilly's stock today.

14.00.2025 - LLY Stock was down 5.1%

• Despite the overall market decline, Eli Lilly's stock price increased by +1.07%.
• The acquisition of Scorpion Therapeutics' early-stage cancer program for $2.5 billion could have positively influenced investor sentiment towards Eli Lilly.
• The anticipation of weight loss resolutions in the new year may have contributed to the optimistic outlook for Eli Lilly's stock.
• Investors holding onto Eli Lilly stock despite a recent 14% fall in the past 3 months indicates confidence in the company's future growth prospects.

31.09.2024 - LLY Stock was up 7.0%

• Despite missing Q3 earnings and revenue estimates, Eli Lilly's stock saw a strong bullish movement, showcasing resilience in the market.
• The bearish movement caused by the company cutting its 2024 forecast was overshadowed by the positive market sentiment towards the pharmaceutical industry as a whole.
• Investors may be focusing on the company's impressive year-to-date gain and potential stock split speculation, leading to increased buying interest despite the recent setbacks in earnings and guidance.
• The overall bullish market movement and positive sentiment towards pharmaceutical companies could have contributed to Eli Lilly's stock outperforming expectations today.

31.09.2024 - LLY Stock was up 6.9%

• Despite missing Q3 earnings and revenue estimates, Eli Lilly's stock saw a strong bullish movement, showcasing resilience in the face of disappointing financial results.
• The market may have reacted positively due to the anticipation of a potential stock split, fueled by the company's impressive 51% year-to-date gain.
• The overall bullish market movement could be attributed to investors focusing on the long-term growth prospects of Eli Lilly, overlooking the short-term setbacks in the quarterly results.
• It's possible that investors are optimistic about the future pipeline of drugs and treatments from Eli Lilly, leading to increased confidence in the company's ability to rebound from the recent financial challenges.

20.10.2024 - LLY Stock was up 5.2%

• Eli Lilly's stock surged after announcing positive Phase 2 results for muvalaplin, an investigational drug that showed promising efficacy in reducing sticky cholesterol levels by almost 86%.
• Investor sentiment was further boosted by a notable endorsement on a financial media show, where the recommendation to buy Eli Lilly stock was made, citing its potential despite being previously unpopular.
• The detailed Phase 3 data release showing impressive results from a study of tirzepatide also contributed to the positive market response, indicating strong growth prospects for Eli Lilly in the pharmaceutical sector.

06.01.2025 - LLY Stock was up 3.1%

• Q4 earnings report for Eli Lilly exceeded expectations, showing a 45% YoY revenue increase driven by strong demand for Mounjaro and Zepbound.
• The company's 2025 sales forecast of $58B-$61B, with a 32% growth midpoint, fueled investor optimism and contributed to the bullish momentum in the stock.
• Analysts are bullish on LLY, with price targets averaging $1066, indicating a 27% upside potential, supported by the anticipated success of new medicines and expanded market launches.
• The positive sentiment surrounding Eli Lilly's earnings and future prospects likely led to the strong bullish movement in the stock today.

14.00.2025 - LLY Stock was down 6.3%

• Eli Lilly cut its Q4 revenue guidance, expecting around $5.5 billion in sales from weight loss/diabetes drugs, leading to a bearish sentiment among investors.
• The acquisition of Scorpion Therapeutics' early-stage cancer program for $2.5 billion might have raised concerns about the company's future expenses and profitability.
• The comparison with Novo Nordisk as the best weight loss stock for 2025 could have shifted investor focus and triggered profit-taking in Eli Lilly shares.
• Despite the recent decline in stock price, analysts suggest holding onto Eli Lilly due to its robust growth prospects, indicating a potential rebound in the future.